Special Call Announcement: Aclaris Therapeutics, Inc. Update on Business Development, Financial Performance, and Corporate Strategy

News">

Aclaris therapeutics Hosts R&D Day, Outlines Future Direction

New York, NY – October 14, 2025 – Aclaris Therapeutics, Inc. convened a Special Call and Research & Development Day today in New York City, bringing together key personnel and industry observers to discuss the company’s pipeline and strategic outlook. The event featured presentations from a number of Aclaris leaders, including William Roberts, Senior Vice President of Corporate Communications & Investor Relations, and Neal Walker, the company’s Co-Founder, CEO, and Chairman.

Key Personnel and Participants

Several high-ranking Aclaris executives were present, including Roland Kolbeck, Chief Scientific Officer; Joseph Monahan, Founder, Chairman of the Board & Chief Scientific Officer; Hugh M. Davis,President,COO & Director; Jesse Hall,Chief Medical Officer; and Zuzana Diamant and michael Cameron.A robust list of conference call participants engaged with the company, including representatives from Cantor fitzgerald, Leerink Partners, Jefferies, Stifel, guggenheim Securities, and Piper Sandler.

Forward-Looking Statements and Risk Disclosure

William Roberts initiated the presentation with the crucial matter of forward-looking statements, referencing the stipulations of the Private Securities Litigation Reform Act of 1995.Roberts emphasized that all statements made during the presentation reflect the company’s judgment as of today, October 14, 2025, and are subject to inherent risks and uncertainties. investors are directed to Aclaris’ filings with the Securities and Exchange Commission for a more comprehensive understanding of potential risk factors.

Did You Know? The Private Securities Litigation Reform Act of 1995 was enacted to encourage companies to provide forward-looking facts to investors, while together protecting them from undue legal liability.

Focus on Research and Development

The core of the day revolved around detailed insights into Aclaris’ ongoing Research and Development initiatives. While specific details of the scientific presentations are not promptly available, the event signals a commitment to innovation within the pharmaceutical sector. Aclaris’ dedication to R&D is critical in an industry where constant advancement is essential for sustained growth.According to recent reports from statista, pharmaceutical R&D spending globally reached over $280 billion in 2023, highlighting the importance of continuous investment in this area.

Pro Tip: When evaluating pharmaceutical companies, always assess their R&D pipeline and the potential of their lead compounds. A strong pipeline indicates a commitment to future growth and a more resilient buisness model.

Executive	Title
William Roberts	Senior VP of Corporate Communications & Investor Relations
Neal Walker	Co-Founder, CEO & Chairman
Roland Kolbeck	Chief Scientific Officer

The Importance of R&D Days in the Pharmaceutical Industry

Research and Development (R&D) Days are a cornerstone of investor relations for pharmaceutical and biotechnology companies. These events provide a platform to showcase cutting-edge research, present clinical trial data, and articulate a long-term strategic vision. They are crucial for attracting investment, building confidence among stakeholders, and signaling a commitment to innovation. The ability to effectively communicate complex scientific information to a diverse audience is a key skill for pharmaceutical leadership.

Frequently Asked Questions about Aclaris Therapeutics

• What is Aclaris Therapeutics’ primary focus? Aclaris Therapeutics is a pharmaceutical company focused on developing innovative therapies for dermatological conditions and other inflammatory diseases.
• What are forward-looking statements? These are statements about expected future results, and they are subject to risks and uncertainties.
• Why are R&D days critically important for pharmaceutical companies? R&D days allow companies to share their progress and future plans with investors and analysts.
• what is the private Securities Litigation Reform Act? It’s a law that provides a safe harbor for forward-looking statements made by public companies.
• Where can I find more information about Aclaris Therapeutics’ risks? Detailed information about risks is available in Aclaris’ filings with the Securities and Exchange Commission.

What are your thoughts on Aclaris’ strategy given these recent updates? Share your insights in the comments below!

Do you think R&D days effectively communicate a company’s vision to investors?

What specific milestones related to A-2019’s clinical progress are anticipated to be discussed on the call?

Recent Business Development Highlights – Aclaris Therapeutics

Aclaris Therapeutics, Inc. (NASDAQ: ACRS) recently announced a special call to discuss key updates across its business development initiatives, financial performance, and evolving corporate strategy.This update is crucial for investors and industry watchers tracking the company’s progress in dermatology and related therapeutic areas. The call, scheduled for[InsertDate/timeofCall-[InsertDate/timeofCall-This facts needs to be added], will provide a detailed overview of recent achievements and future outlook.

Key areas of focus within Aclaris’s business development include:

* Pipeline Advancement: Updates on clinical trials for lead candidates, including A-2019 for the treatment of seborrheic dermatitis and other inflammatory skin conditions. Expect discussion on trial timelines, patient enrollment, and preliminary data.

* Partnerships & Licensing: any new collaborations or licensing agreements aimed at expanding Aclaris’s product portfolio or geographic reach. This is a significant area for potential growth.

* Strategic acquisitions: Discussion of potential acquisition targets or opportunities to bolster the company’s position in the dermatology market.

* Commercial expansion: Details on the continued rollout and market penetration of existing products like ZILXI (minocycline topical,4%),a first-in-class topical minocycline for the treatment of inflammatory acne.

Financial Performance Review – Q3 2025 Expectations

The call will also delve into Aclaris’s financial performance,likely covering the third quarter of 2025. Investors will be keen to hear about:

* Revenue Growth: Analysis of revenue generated from ZILXI and other commercial products. Focus will be on year-over-year growth and market share gains.

* Gross margin: Examination of the company’s gross margin, reflecting the cost of goods sold and manufacturing efficiency.

* Operating Expenses: A breakdown of research and development (R&D) and selling, general, and administrative (SG&A) expenses. Investors will assess whether these expenses are aligned with the company’s growth strategy.

* Cash Position: An update on Aclaris’s cash reserves and runway, crucial for funding ongoing clinical trials and commercialization efforts.

* Key Financial Metrics: Discussion of vital financial ratios and indicators, such as earnings per share (EPS) and return on investment (ROI).

corporate Strategy – Navigating the Dermatology Landscape

Aclaris’s corporate strategy is evolving to address the dynamic dermatology market. The call is expected to outline:

* Focus Areas: Clarification of the company’s core therapeutic areas of focus, perhaps including acne, seborrheic dermatitis, psoriasis, and atopic dermatitis.

* R&D Priorities: A detailed look at the company’s research and development pipeline, including prioritization of programs and investment decisions.

* Commercialization Strategy: How Aclaris plans to maximize the commercial potential of its products, including marketing campaigns, sales force expansion, and market access initiatives.

* Long-Term vision: A presentation of the company’s long-term goals and objectives, including potential for future growth and value creation.

* Investment in Innovation: Aclaris’s commitment to innovative dermatology solutions, including novel drug delivery systems and therapeutic approaches.

ZILXI Performance & Market Analysis

ZILXI, Aclaris’s flagship product, remains a key driver of revenue. The call will likely provide an in-depth analysis of its performance:

* Prescription Trends: Updates on ZILXI prescription volume and growth rates.

* Market Penetration: Assessment of ZILXI’s market share within the inflammatory acne treatment space.

* Physician Feedback: insights into physician adoption and patient response to ZILXI.

* Competitive Landscape: Discussion of the competitive landscape and Aclaris’s strategies for differentiating ZILXI from other acne treatments.

* Reimbursement Coverage: Updates on insurance coverage and reimbursement for ZILXI.

Potential Catalysts & Investor Considerations

Several potential catalysts could impact Aclaris’s stock price in the coming months:

* Clinical Trial Data: Positive data from ongoing clinical trials for A-2019 or other pipeline candidates.

* Regulatory Approvals: Potential FDA approvals for new indications or formulations of existing products.

* Partnership Announcements: New collaborations or licensing agreements that expand Aclaris’s product portfolio.

* Financial Performance: Strong revenue growth and profitability.

* Market Trends: increasing demand for innovative dermatology treatments.

investors should carefully consider these